Insulet Corporation (PODD)

$195.03

+0.07

(+0.04%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $192.10
    $198.17
    $195.03
    downward going graph

    1.5%

    Downside

    Day's Volatility :3.06%

    Upside

    1.58%

    downward going graph
  • $125.82
    $286.71
    $195.03
    downward going graph

    35.49%

    Downside

    52 Weeks Volatility :56.12%

    Upside

    31.98%

    downward going graph

Returns

PeriodInsulet CorporationSector (Health Care)S&P500
3 Months
18.62%
6.4%
10.8%
6 Months
-5.34%
6.0%
13.7%
1 Year
-30.05%
9.6%
21.4%
3 Years
-28.53%
14.8%
27.3%

Highlights

Market Capitalization
13.7B
Book Value
$11.29
Earnings Per Share (EPS)
3.33
PE Ratio
58.55
PEG Ratio
3.15
Wall Street Target Price
233.07
Profit Margin
13.14%
Operating Margin TTM
12.88%
Return On Assets TTM
6.74%
Return On Equity TTM
36.18%
Revenue TTM
1.8B
Revenue Per Share TTM
25.5
Quarterly Revenue Growth YOY
23.3%
Gross Profit TTM
805.6M
EBITDA
339.4M
Diluted Eps TTM
3.33
Quarterly Earnings Growth YOY
1.16
EPS Estimate Current Year
3.08
EPS Estimate Next Year
3.72
EPS Estimate Current Quarter
0.39
EPS Estimate Next Quarter
0.56

Analyst Recommendation

Buy
    82%Buy
    17%Hold
    0
    0%Sell
Based on 28 Wall street analysts offering stock ratings for Insulet Corporation(by analysts ranked 0 to 5 stars)
Based on 28 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
23
23
23
Hold
5
5
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 19.5%

Current $195.03
Target $233.07

Company Financials

FY18Y/Y Change
Revenue
563.8M
↑ 21.57%
Net Income
3.3M
↓ 112.27%
Net Profit Margin
0.58%
↑ 6.37%
FY19Y/Y Change
Revenue
738.2M
↑ 30.93%
Net Income
11.6M
↑ 252.37%
Net Profit Margin
1.57%
↑ 0.99%
FY20Y/Y Change
Revenue
904.4M
↑ 22.51%
Net Income
6.8M
↓ 41.38%
Net Profit Margin
0.75%
↓ 0.82%
FY21Y/Y Change
Revenue
1.1B
↑ 21.49%
Net Income
16.8M
↑ 147.06%
Net Profit Margin
1.53%
↑ 0.78%
FY22Y/Y Change
Revenue
1.3B
↑ 18.79%
Net Income
4.6M
↓ 72.62%
Net Profit Margin
0.35%
↓ 1.18%
FY23Y/Y Change
Revenue
1.7B
↑ 30.02%
Net Income
206.3M
↑ 4384.78%
Net Profit Margin
12.16%
↑ 11.81%
Q4 FY22Q/Q Change
Revenue
369.7M
↑ 8.48%
Net Income
17.0M
↓ 426.92%
Net Profit Margin
4.6%
↑ 6.13%
Q1 FY23Q/Q Change
Revenue
358.1M
↓ 3.14%
Net Income
23.8M
↑ 40.0%
Net Profit Margin
6.65%
↑ 2.05%
Q2 FY23Q/Q Change
Revenue
396.5M
↑ 10.72%
Net Income
27.3M
↑ 14.71%
Net Profit Margin
6.89%
↑ 0.24%
Q3 FY23Q/Q Change
Revenue
432.7M
↑ 9.13%
Net Income
51.9M
↑ 90.11%
Net Profit Margin
11.99%
↑ 5.1%
Q4 FY23Q/Q Change
Revenue
509.8M
↑ 17.82%
Net Income
103.3M
↑ 99.04%
Net Profit Margin
20.26%
↑ 8.27%
Q1 FY24Q/Q Change
Revenue
441.7M
↓ 13.36%
Net Income
51.5M
↓ 50.15%
Net Profit Margin
11.66%
↓ 8.6%
FY18Y/Y Change
Total Assets
928.7M
↑ 13.71%
Total Liabilities
716.6M
↑ 8.87%
FY19Y/Y Change
Total Assets
1.1B
↑ 23.06%
Total Liabilities
1.1B
↑ 48.89%
FY20Y/Y Change
Total Assets
1.9B
↑ 63.87%
Total Liabilities
1.3B
↑ 18.96%
FY21Y/Y Change
Total Assets
2.0B
↑ 9.39%
Total Liabilities
1.5B
↑ 17.58%
FY22Y/Y Change
Total Assets
2.3B
↑ 9.87%
Total Liabilities
1.8B
↑ 18.91%
FY23Y/Y Change
Total Assets
2.6B
↑ 14.97%
Total Liabilities
1.9B
↑ 4.55%
Q4 FY22Q/Q Change
Total Assets
2.3B
↑ 3.92%
Total Liabilities
1.8B
↑ 2.1%
Q1 FY23Q/Q Change
Total Assets
2.3B
↑ 1.69%
Total Liabilities
1.8B
↑ 0.65%
Q2 FY23Q/Q Change
Total Assets
2.4B
↑ 4.22%
Total Liabilities
1.8B
↑ 2.55%
Q3 FY23Q/Q Change
Total Assets
2.5B
↑ 3.43%
Total Liabilities
1.9B
↑ 1.54%
Q4 FY23Q/Q Change
Total Assets
2.6B
↑ 4.88%
Total Liabilities
1.9B
↓ 0.25%
Q1 FY24Q/Q Change
Total Assets
2.6B
↑ 1.38%
Total Liabilities
1.8B
↓ 1.2%
FY18Y/Y Change
Operating Cash Flow
35.9M
↓ 12.88%
Investing Cash Flow
-184.5M
↓ 12.47%
Financing Cash Flow
-8.7M
↓ 102.85%
FY19Y/Y Change
Operating Cash Flow
98.4M
↑ 174.1%
Investing Cash Flow
-73.6M
↓ 60.11%
Financing Cash Flow
73.5M
↓ 948.24%
FY20Y/Y Change
Operating Cash Flow
84.0M
↓ 14.63%
Investing Cash Flow
14.0M
↓ 119.02%
Financing Cash Flow
605.5M
↑ 723.81%
FY21Y/Y Change
Operating Cash Flow
-68.1M
↓ 181.07%
Investing Cash Flow
-82.7M
↓ 690.71%
Financing Cash Flow
40.7M
↓ 93.28%
FY22Y/Y Change
Operating Cash Flow
119.0M
↓ 274.74%
Investing Cash Flow
-191.1M
↑ 131.08%
Financing Cash Flow
-40.3M
↓ 199.02%
Q4 FY22Q/Q Change
Operating Cash Flow
50.7M
↓ 10.58%
Investing Cash Flow
-88.4M
↑ 160.77%
Financing Cash Flow
-14.5M
↑ 271.79%
Q1 FY23Q/Q Change
Operating Cash Flow
500.0K
↓ 99.01%
Investing Cash Flow
-42.1M
↓ 52.38%
Financing Cash Flow
-12.1M
↓ 16.55%
Q2 FY23Q/Q Change
Operating Cash Flow
44.0M
↑ 8700.0%
Investing Cash Flow
-23.1M
↓ 45.13%
Financing Cash Flow
3.2M
↓ 126.45%

Technicals Summary

Sell

Neutral

Buy

Insulet Corporation is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Insulet Corporation
Insulet Corporation
-2.15%
-5.34%
-30.05%
-28.53%
61.36%
Stryker Corporation
Stryker Corporation
-0.12%
8.84%
15.17%
33.61%
63.53%
Boston Scientific Corp.
Boston Scientific Corp.
0.73%
27.69%
45.08%
81.26%
82.49%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-2.63%
15.09%
-6.64%
-18.84%
33.76%
Abbott Laboratories
Abbott Laboratories
-4.26%
-10.65%
-8.76%
-14.07%
15.85%
Medtronic Plc
Medtronic Plc
-0.86%
-8.08%
-11.05%
-36.67%
-21.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Insulet Corporation
Insulet Corporation
58.55
58.55
3.15
3.08
0.36
0.07
NA
11.29
Stryker Corporation
Stryker Corporation
37.9
37.9
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.49
63.49
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
36.97
36.97
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
31.57
31.57
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
29.42
29.42
1.52
5.2
0.07
0.04
0.03
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Insulet Corporation
Insulet Corporation
Buy
$13.7B
61.36%
58.55
13.14%
Stryker Corporation
Stryker Corporation
Buy
$126.2B
63.53%
37.9
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$111.1B
82.49%
63.49
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.1B
33.76%
36.97
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$174.1B
15.85%
31.57
13.96%
Medtronic Plc
Medtronic Plc
Buy
$104.1B
-21.49%
29.42
11.36%

Insights on Insulet Corporation

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 509.8M → 441.7M (in $), with an average decrease of 13.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 103.3M → 51.5M (in $), with an average decrease of 50.2% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 45.1% return, outperforming this stock by 75.2%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 81.3% return, outperforming this stock by 109.8%

Institutional Holdings

  • Vanguard Group Inc

    11.71%
  • Capital Research Global Investors

    10.80%
  • BlackRock Inc

    8.60%
  • FMR Inc

    7.71%
  • State Street Corporation

    4.17%
  • Wellington Management Company LLP

    2.84%

Company Information

insulet corporation is an innovative medical device company based in billerica, massachusetts. it was founded in 2000 with the mission of improving the lives of people with diabetes. specifically, through its revolutionary omnipod insulin management system, insulet seeks to expand the use of insulin pump therapy. studies have demonstrated the advantages of insulin pump therapy over multiple daily insulin injections (mdi); these advantages include better glycemic control, fewer hypoglycemic events, reduced glycemic variability1 and improved quality of life2. despite these benefits, most people still choose mdi therapy largely due to the complexity, cost and inconvenience of conventional pump technology. the omnipod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. improvements include omnipod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. by breaking down

Organization
Insulet Corporation
Employees
3000
CEO
Dr. James R. Hollingshead Ph.D.
Industry
Health Technology

FAQs